Interested in training for your team? Click here to learn more

Agency Deference and the Impact of Kisor in Healthcare: Challenging CMS and Other Agency Actions

Recording of a 90-minute CLE webinar with Q&A

This program is included with the Strafford CLE Pass. Click for more information.
This program is included with the Strafford All-Access Pass. Click for more information.

Conducted on Wednesday, September 25, 2019

Recorded event now available

or call 1-800-926-7926

This CLE course will examine judicial deference to agency decisions in light of the recent Supreme Court decision in Kisor v. Wilkie and the implications for the highly regulated healthcare industry. The panel will also guide healthcare counsel in challenging CMS actions.

Description

The Supreme Court issued its decision in Kisor v. Wilkie (U.S. June 26, 2019), addressing the doctrine of agency deference. In a 5-4 decision, the Court declined to overturn Auer but specified significant limitations on its applicability. Kisor may present new opportunities for those in the highly regulated healthcare industry to challenge agency actions.

Following the Kisor decision, along with the Court's decision in Azar v. Allina (U.S. June 3, 2019), the healthcare industry can expect to learn more about agency internal review processes. It will also be necessary to note who at the agency acted. Are decisions made by mid-level officials now vulnerable or at risk? Will decisions at CMS begin to be made at higher levels to maintain deference?

Listen as our authoritative panel of healthcare counsel examines the critical implications and practical application of Kisor for the healthcare industry. The panel will also discuss Auer deference in light of Kisor and Azar v. Allina. The panel will offer guidance to healthcare counsel in challenging CMS and other agency actions.

READ MORE

Outline

  1. Review of Supreme Court's decisions
    1. Kisor v. Wilkie (U.S. June 26, 2019)
    2. Azar v. Allina (U.S. June 3, 2019)
  2. Implications of Kisor for the healthcare industry
  3. What does Kisor mean for Auer deference?
  4. Practical guidance and strategies

Benefits

The panel will review these and other key issues:

  • What are the practical implications of the Supreme Court's decision in Kisor v. Wilkie for the healthcare industry
  • What is the status of Chevron and Auer deference?
  • How do these cases impact the tools available to CMS and other federal agencies in regulatory litigation?
  • What are best practices for challenging CMS agency actions based on recent decisions?

Faculty

Brouillette, Mimi
Mimi Hu Brouillette

Of Counsel
Greenberg Traurig

Ms. Brouillette focuses her practice on healthcare reimbursement, regulatory, and transactional matters. She advises...  |  Read More

Gustafson, Jessica
Jessica L. Gustafson

Founding Shareholder
The Health Law Partners

Ms. Gustafson practices in all areas of health care law and devotes a substantial portion of her practice to...  |  Read More

Jarcho, Daniel
Daniel Jarcho

Partner
Alston & Bird

Mr. Jarcho is a litigation partner at Alston & Bird LLP’s Washington, D.C. office.  He represents...  |  Read More

Access Anytime, Anywhere

Strafford will process CLE credit for one person on each recording. All formats include course handouts.

To find out which recorded format will provide the best CLE option, select your state:

CLE On-Demand Video

Download